Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis - PubMed (original) (raw)

. 2006 Jun;43(6):1267-75.

doi: 10.1002/hep.21181.

Affiliations

• PMID: 16628605
• DOI: 10.1002/hep.21181

Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis

Tsutomu Fujii et al. Hepatology. 2006 Jun.

Abstract

The pituitary tumor transforming gene 1 (PTTG1) protein is cell-cycle regulated and is identified as a human securin that inhibits sister chromatid separation and is involved in transformation and tumorigenesis. PTTG1 has very low or undetectable expression in most normal human tissues, but it is abundantly expressed in malignant cell lines and pituitary tumors. In this study, we investigated human PTTG1 expression in 62 hepatocellular carcinoma (HCC) specimens using quantitative real-time reverse transcription polymerase chain reaction analysis. We found that, compared with corresponding noncancerous liver tissues, PTTG1 was remarkably overexpressed in HCCs (PTTG1/beta-actin; 0.443 +/- 0.073 vs. 0.068 +/- 0.007; P < .0001). Furthermore, we found a significant correlation between PTTG1 expression and serum alpha-fetoprotein level (P < .001). Univariate and multivariate analyses revealed that the PTTG1 messenger RNA (mRNA) expression was an independent prognostic factor for disease-free (odds ratio 2.70; P = .037) and overall (odds ratio 5.35; P = .007) survival. Moreover, we discovered a significant relationship between PTTG1 expression and intratumoral microvessel density. Our data supported an important role for PTTG1-mediated upregulation of fibroblast growth factor (FGF)-2, one of angiogenesis and modulation of tumor progression, in hepatocarcinogenesis. In conclusion, PTTG1 might be critically involved in the development of HCCs through the promotion of angiogenesis. PTTG1 is overexpressed in HCC and our results suggest that PTTG1 mRNA expression has prognostic significance for the survival of postoperative patients with HCC.

PubMed Disclaimer

Comment in

• Pituitary tumor transforming gene 1 in the liver.
  Grizzi F, Franceschini B, Musardo S, Frezza EE, Cobos E, Chiriva-Internati M. Grizzi F, et al. Hepatology. 2006 Dec;44(6):1701-2. doi: 10.1002/hep.21428. Hepatology. 2006. PMID: 17133495 No abstract available.

Similar articles

• Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma.
  Chen RN, Huang YH, Yeh CT, Liao CH, Lin KH. Chen RN, et al. Cancer Res. 2008 Mar 15;68(6):1697-706. doi: 10.1158/0008-5472.CAN-07-5492. Cancer Res. 2008. PMID: 18339849
• Overexpression of pituitary tumor-transforming gene-1 in hepatocellular carcinoma.
  Su MC, Hsu HC, Liu YJ, Jeng YM. Su MC, et al. Hepatogastroenterology. 2006 Mar-Apr;53(68):262-5. Hepatogastroenterology. 2006. PMID: 16608036
• Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
  Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, Wu W, Qiu LW, Meng XY. Yao DF, et al. Hepatobiliary Pancreat Dis Int. 2005 May;4(2):220-6. Hepatobiliary Pancreat Dis Int. 2005. PMID: 15908319
• Transcriptional targets for pituitary tumor-transforming gene-1.
  Tong Y, Eigler T. Tong Y, et al. J Mol Endocrinol. 2009 Nov;43(5):179-85. doi: 10.1677/JME-08-0176. Epub 2009 May 11. J Mol Endocrinol. 2009. PMID: 19433493 Review.
• Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
  Pang R, Poon RT. Pang R, et al. Cancer Lett. 2006 Oct 28;242(2):151-67. doi: 10.1016/j.canlet.2006.01.008. Epub 2006 Mar 27. Cancer Lett. 2006. PMID: 16564617 Review.

Cited by

• Development and validation of an eight-gene signature based predictive model to evaluate the prognosis of hepatocellular carcinoma patients: a bioinformatic study.
  Zhang J, Fu X, Zhang N, Wang W, Liu H, Jia Y, Nie Y. Zhang J, et al. Ann Transl Med. 2022 May;10(9):524. doi: 10.21037/atm-22-1934. Ann Transl Med. 2022. PMID: 35928748 Free PMC article.
• Identification of hub genes and biological pathways in hepatocellular carcinoma by integrated bioinformatics analysis.
  Zhao Q, Zhang Y, Shao S, Sun Y, Lin Z. Zhao Q, et al. PeerJ. 2021 Jan 19;9:e10594. doi: 10.7717/peerj.10594. eCollection 2021. PeerJ. 2021. PMID: 33552715 Free PMC article.
• inFRank: a ranking-based identification of influential genes in biological networks.
  Cui X, Li X, Li J, Wang X, Sun W, Cheng Z, Ding J, Wang H. Cui X, et al. Oncotarget. 2017 Jul 4;8(27):43810-43821. doi: 10.18632/oncotarget.11878. Oncotarget. 2017. PMID: 27623074 Free PMC article.
• Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response.
  Xu Q, Gu J, Lv Y, Yuan J, Yang N, Chen J, Wang C, Hou X, Jia X, Feng L, Yin G. Xu Q, et al. Oncol Lett. 2018 Mar;15(3):3437-3446. doi: 10.3892/ol.2018.7734. Epub 2018 Jan 5. Oncol Lett. 2018. PMID: 29467868 Free PMC article.
• Promising diagnostic and prognostic value of six genes in human hepatocellular carcinoma.
  Zhang G, Kang Z, Mei H, Huang Z, Li H. Zhang G, et al. Am J Transl Res. 2020 Apr 15;12(4):1239-1254. eCollection 2020. Am J Transl Res. 2020. PMID: 32355538 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information